The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay(University of San Diego), Toni K. Choueiri(Dana-Farber Cancer Institute)Cancer Immunology ResearchMay 10, 201810.1158/2326-6066.cir-17-0475Cited by 136SaveCiteExport RISWatch citationsRelated PapersUpdated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma|Annals of Oncology|2020|457